Predicta Biosciences and CIMA LAB Diagnostics Announce Agreement to Advance Ultrasensitive Blood-Based Diagnostics for Multiple Myeloma and Other Hematological Malignancies

Precede Biosciences Presents New ASCO 2026 Data Demonstrating Ability of Precede Bio Insight™ to Decode MET-Driven Biology and Resistance in Advanced NSCLC

Predicta Biosciences Appoints Dr. Craig L. Tendler as Independent Director to its Board

Neomorph Appoints Biopharma Leader Robert J. Hugin as Chairman of the Board

Precede 2026 AACR Poster: Plasma-based comprehensive epigenomic profiling enables multiplexed prediction of target gene expression and detection of resistance mechanisms

Precede Launches Precede Bio Insight, a Genome-wide Liquid Biopsy for Functional Tumor Biology

Precede 2026 AACR Poster

Predicta Poster: Whole genome sequencing of multiple myeloma genomes with a novel clinical assay enables identification of genetic alterations underlying immunotherapy resistance

Precede 2026 AACR Poster: Characterization of Functional Estrogen Receptor (ER) Dependence via Comprehensive Epigenomic Liquid Biopsy Stratifies Endocrine Therapy (ET) Responders with Metastatic
Breast Cancer (MBC)

Tempus and Predicta Biosciences Announce Collaboration to Expand Life Sciences Access to Ultrasensitive Whole-Genome Sequencing Assay for Hematologic Malignancies and MRD Monitoring

Neomorph to Highlight Progress in Targeted Protein Degradation Science at the American Association for Cancer Research Annual Meeting

Neomorph Announces Closing of $100 Million Series B Financing

NextPoint Tx Announces Clinical Entry of NPX372 a First in Class B7-H7 Targeted T Cell Engager to Treat Solid Tumors

Neomorph Announces First Patient Dosed in Phase 1/2 Trial Evaluating NEO-811 For the Treatment of Locally Advanced or Metastatic Non-Resectable Clear Cell Renal Cell Carcinoma

Precede Biosciences Secures $83.5M in Total Financing to Scale Next-Generation Precision Diagnostics Platform

GenoPredicta Product Guide